Dr Reddys Laboratories launches Carmustine for Injection in US market

Dr Reddys Laboratories launches Carmustine for Injection in US market

Oct 16, 2021 12:10 IST capital market

Dr Reddys Laboratories announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU? (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

The BiCNU? brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health.

Dr. Reddys Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.

Powered by Capital Market - Live News

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity